近期,河北医科大学第四医院刘月平教授发表了一篇综述报道《HER2-low breast cancer: insights on pathological testing》,旨在深入探讨HER2低表达乳腺癌的最新检测指南及进展,以期规范和完善该疾病的病理检测流程,为乳腺癌患者提供更加精准和个性化的治疗方案。 ...
相关论文于当地时间8月22日在线发表于国际知名期刊《自然-通讯》（Nature Communications），题为“Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer”，这也是该研究在2022年圣安东尼奥乳腺癌大会（SABCS）入选亮点讨论后的正式见刊。邵志敏、江一舟团队论...
Wang HB. Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study. Front Oncol. 2023 Mar 29;13:1130734. doi: 10.3389/fonc.2023.1130734. PMID: 37064...
HER2-low乳腺癌在不同分子亚型中的特征方面:在Luminal型乳腺癌中,PIK3CB、ACVR18、HGF和ERG是HER2-low亚组与HER2-0亚组之间突变频率显著不同的关键基因(见图2b);在三阴性乳腺癌(TNBC)中,HER2-low亚组与HER2-0亚组之间突变频率差异显著的主要基因为FGFR3、ATRX和IGF1R(见图2c)。值得注意的是,所有在TNBC中...
总之，HER2-low与ER-low乳腺癌属于极具挑战性的诊断类别，迫切需要更加精细化和个性化的临床治疗策略。通过深化对这两种乳腺癌亚型的认知，并据此调整相应的诊疗措施，我们期望能够为患者带来更大生存获益。参考文献：[1]Fusco N, Viale G. The "lows": Update on ER-low and HER2-low breast cancer. Breast. ...
24,12795.[3] Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, CuriglianoG, Criscitiello C, Fusco N. HER2 Low, Ultra-low, and Novel ComplementaryBiomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. FrontMol Biosci. 2022 Mar 15; 9:834651.
low breast cancer (433 female and one male) and integrated genomic, transcriptomic, proteomic, and metabolomic profiling data. In this cohort, HER2-low tumors are more distinguished from HER2-0 tumors in the hormone receptor-negative subgroup. Within HER2-low tumors, significant interpatient ...
2. Tarantino P, Hamilton E, Tolaney S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. Journal of Clinical Oncology, 2020, 38(17): 1951-1962. 3. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast ca...
Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone receptor and human epidermal growth factor receptor 2 (HER2) expression status. "HER2-low" tumors, which exhibit a low level of HER2 expression (immunohistochemistry 1 or 2 without gene amplification), were...
得分>199的患者从HER2-0转为HER2-low/阳性状态的几率相对较高。该工具可帮助临床医生筛选出原发灶HER2-0且HER2状态转换概率较高的患者,并建议他们进行复发/转移灶再活检,进而帮助快速筛选出T-DXd治疗的潜在获益人群。 参考文献 Breast Cancer Res Treat. 2023 Dec 8. IF: 3.8...